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Background: Chronic Pseudomonas aeruginosa lung infection is the major reason for premature death in patients with cystic fibrosis (CF).
Infected patients experience a progressive deterioration of the lung tissue caused by a persistent accumulation of PMNs. We investigated if
the pulmonary accumulation of PMNs is reflected as a migration of PMNs through the blood in chronically infected CF patients.
Methods: Blood and sputum samples from 37 stable, chronically (CF+P) and 6 non-infected (CFP) CF patients without exacerbations
were compared using FACS, leukocyte counting, and ELISA. Within the CF+P patients, the blood parameters were compared to the lung
function (FEV1 and FVC) and to the sputum. Similar measurements were performed on 15 chronically infected CF patients before and after
elective antibiotic treatment.
Results: In the CF+P patients the concentration of G-CSF in the sera and PMNs in the blood was increased and correlated to poor lung
function. However, only the concentration of G-CSF in the sera was correlated to the concentration of TNF-a in the sputum. After the
antibiotic treatment, the lung function was improved and the concentration of PMNs in the blood and G-CSF in the sera was reduced.
Conclusion: G-CSF in the sera may contribute to the pulmonary inflammation in CF patients with chronic P. aeruginosa lung infection by
regulating the number of PMNs available for migration and may be considered as an indicator of clinical status.
D 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Pseudomonas aeruginosa; Cystic fibrosis; Lung infection; G-CSF; PMNs1. Introduction
Cystic fibrosis (CF) is the most common lethal disorder
with autosomal recessive heredity in Caucasians [1]. The
disease is caused by mutations in a single gene of chro-
mosome 7, which encodes the CF transmembrane regulator
gene (CFTR) [2]. CFTR is an epithelial chloride channel
and mutations affect apical ion and water transport leading
to viscous sescretion and impaired mucociliary clearance in
the CF airways [3].1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.12.004
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E-mail address: pojensen@excite.com (P.Ø. Jensen).The majority of patients with CF acquire chronic
Pseudomonas aeruginosa lung infection after a period of
intermittent infections [4]. Although the host factors
responsible for the establishment of the chronic infection
are not yet clear the chronic infection is characterized by
biofilm formation [4] and the presence of numerous
polymorphonuclear leukocytes (PMNs) in the lungs sur-
rounding the microcolonies [4,5]. Despite the various
antibacterial defense mechanisms of the PMNs the bacteria
persist. Resistance to the PMNs is provided by formation of
mucoid biofilm [6,7], but the antibacterial activity of the
PMNs may also be inhibited by Quorum Sensing—
regulated virulence factors [8] and local hypoxia in the CF
lungs [9]. Instead of clearing the bacteria, proteolytic
enzymes [10] and superoxide [11] released by the PMNs5 (2006) 145 – 151ed by Elsevier B.V. All rights reserved.
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responsible for the premature death in CF [4]. In addition,
the persistent accumulation of PMNs in the lungs may
obstruct the airways [12] and the DNA from necrotic PMNs
increases the viscosity of the sputum [13,14]. More than 108
PMNs per ml sputum may be found in the lungs of CF
patients with chronic P. aeruginosa lung infection [12] and
considering the short life span of the PMNs, the normal pool
of circulating PMNs may be insufficient to sustain the
persistent high number of PMNs in the lungs. Thus, a
supply of PMNs from the bone marrow is expected to be
mobilized into the blood in order to migrate into the infected
lungs. In this study, we hypothesized that the migration of
PMNs is detectable in the blood by the number and
activation of the PMNs and by the concentration of
cytokines regulating the migration via the blood of CF
patients with chronic P. aeruginosa lung infection.
The experiment was carried out by comparing blood
samples from stable, chronically infected CF patients
without exacerbations and non-infected CF patients using
flow cytometry, leukocyte counting, and ELISA. In addi-
tion, we estimated the relation between the lung function,
the concentration of PMNs and the proinflammatory
cytokines in the blood of CF patients with chronic P.
aeruginosa lung infection. The finding from these groups of
patients were further verified by comparing the same
parameters in stable, chronically infected CF patients
without exacerbations before and after attenuation of the
lung inflammation by elective antibiotic treatment [15,16].2. Materials and methods
2.1. Patients
Cross-sectional: 43 patients with CF were included. The
diagnosis of CF was based on abnormal sweat electrolytes,
characteristic clinical features, and detection of specific
mutations. The CF patients were divided in two groups:
A) Thirty-seven stable CF patients (24 males and 13
females, median age 26, range 16–38 years) with
chronic P. aeruginosa lung infection (CF + P) without
excacerbations receiving 2 weeks elective courses of
i.v. anti-pseudomonal antimicrobial treatment on a
regular basis every third month [17]. Chronic infec-
tion was defined as 6 months of continuous
colonization or shorter, but with 2 or more precipitins
against P. aeruginosa [18]. In order to minimize
variation patients were included 1 to 2 months after
the i.v. elective treatment.
B) Six CF patients (3 males and 3 females, median age 19,
range 16–29 years) without chronicP. aeruginosa lung
infection and no other signs of lung infection (CF–P).
C) Seven normal volunteers (3 males and 4 females,
median age 24, range 18–37 years).Longitudinal: Fifteen stable CF patients (9 males and 6
females, median age 30, range 17–52 years) with chronic P.
aeruginosa lung infection without exacerbations before and
after regular elective course of i.v. anti-pseudomonal
antimicrobial treatment with an aminoglycoside and a h-
lactam for 2 weeks.
2.2. Sampling
Sera and heparinized peripheral blood samples were
obtained by venous puncture. Sera was collected in
VACUTAINERS (367615, Becton Dickinson, Copenhagen,
Denmark). Anti-coagulated blood was collected in VACU-
TAINERS (368484, Becton Dickinson). Sputum samples
were centrifuged (8500 g, 4 h, 4 -C). The supernatant was
stored at 80 -C until measurement of cytokines.
2.3. Leukocyte counting
The concentration of leukocytes in the blood was
estimated by routine counting in the central laboratory.
2.4. Staining for flow cytometry of PMNs and activation
markers
Erythrocytes were removed by adding cold lysing-buffer
(8.02 g/l NH4Cl, 0.84 g/l NaHCO3, 0.37 g/l EDTA in MilliQ
water). The remaining leukocytes were washed in cold
phosphate buffered saline (PBS) without Ca2+ and Mg2+
before staining. All antibodies were purchased from
Pharmingen (San Diego, CA, US). Lysed blood was double
stained with the PMN phenotypic surface marker, mono-
clonal phycoerythrin conjugated mouse anti-CD15 antibody
(IgGM, n, clone: HI98). To estimate the activation of
circulating PMNs during the reduction of the lung inflam-
mation by the elective antibiotic treatment, PMN activation
markers were stained with monoclonal fluorescein isothio-
cyanate conjugated mouse anti-CD16 antibody (IgG1, n,
clone: 3G8) or anti-CD62L antibody (IgG1, n, clone: Dreg
56). The cells were incubated on ice in the dark for 30 min
and washed once in cold PBS. The samples were analyzed
using a FACSort (Becton Dickinson) equipped with a
15 mW argon-ion laser tuned at 488 nm for excitation.
Light scatter and logarithmically amplified fluorescence
parameters from 10,000 events were recorded in list mode
after gating on forward light scatter to avoid debris, cell
aggregates and bacteria. The instrument was calibrated
using Calibrite (Becton Dickinson) and the specific fluo-
rescence was calculated by subtracting the fluorescence
intensity from samples stained with irrelevant isotypic
control antibodies.
2.5. Cytokines
The concentration of G-CSF and IL-8 in the sera was
measured by Quantikine (R&D Systems, Abingdon, UK)
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Fig. 1. The concentration of PMNs in the blood of CF patients with chronic
P. aeruginosa lung infection (n =31) and in non-infected CF patients
(n =6). The lines show the medians. Normal reference interval: 1.8–
7.4109 PMNs pr l. Data were analyzed by Mann–Whitney test.
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ELISA kits according to the instructions of the manufac-
turer. Samples were measured in duplicates. The sensitivity
was less than 1 pg/ml for all three cytokines. The range of
the G-CSF standard curve was 1.25–80 pg/ml, the range of
the IL-8 standard curve was 31.2–2000 pg/ml, and the
range of the TNF-a standard curve was 7.8–500 pg/ml. To
minimize variation, each entire set of samples for ELISA
was run on the same day by the same person. Based on the
standard curves, the CV did not exceed 20%.
2.6. Lung function
Lung function was assessed by spirometry (Pneumotach,
Dra¨ger, Germany). Forced vital capacity (FVC) and forced
expiratory volume in 1 s (FEV1) was recorded. Both0
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Fig. 2. This figure shows the concentration of G-CSF and IL-8 in the sera of CF pa
CF patients (n =6). The concentration of cytokines was measured with ELIZA as p
by Mann–Whitney test.parameters were expressed as percentage of predicted values
corrected for gender and height [19].
2.7. Statistics
Data were analyzed by Mann–Whitney test, Spearman
Rank test, and Wilcoxon signed pair-differences rank test
using Staview 4.51 (Abacus Concepts, Inc., Berkeley, CA,
US) software for Macintosh. P0.05 was considered
statistically significant.3. Results
3.1. PMNs in the blood (Fig. 1)
A higher concentration of neutrophils was seen in the
blood of the CF+P patients ( p <0.02; Fig. 1). The
concentration of PMNs in the blood was obtained from 31
of the 37 CF+P patients and in all 6 CFP.
3.2. Cytokines in sera (Fig. 2)
The concentration of G-CSF was increased in the sera of
the CF+P patients ( p <0.001; Fig. 2). In contrast, the
concentration of IL-8 was higher in the sera of the CF-P
patients ( p <0.006). The concentration of cytokines in sera
was measured in all CF patients.
3.3. Lung inflammation and G-CSF in the blood (Fig. 3)
In 31 CF+P patients sputum samples were obtained
allowing the concentration of TNF-a in the sputum to be
used as a marker of lung inflammation (Fig. 3). The
concentration of G-CSF in the sera was correlated to the0
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tients with chronic P. aeruginosa lung infection (n =37) and in non-infected
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Fig. 3. Correlation between concentration of G-CSF in the sera and the
concentration of TNF-a in the sputum from CF patients with chronic P.
aeruginosa lung infection (n =31). Correlation was evaluated by Spear-
mann Rank test ( p <0.006, Rho=0.475).
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Rho=0.475). No significant correlation could be demon-
strated between the concentration of TNF-a in the sputumC D
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Fig. 4. Correlation between the lung function expressed as percentage of predict
concentration of PMNs in the blood (n =29) and the concentration of G-CSF in t
PMNs and FEV1 ( p <0.03, Rho=0.400). (B) PMNs and FVC ( p <0.03, Rho=
FVC ( p <0.02, Rho=0.400).and the concentration of PMNs in the blood or the
concentration of IL-8 in the sera (data not shown).
3.4. Lung function and PMNs and cytokines in the blood
(Fig. 4)
In the CF+P patients, the concentration of PMNs in the
blood was inversely correlated to the FEV1( p<0.03, Rho=
0.400) and to the FVC ( p <0.03, Rho=0.421). Estima-
tions of lung function and the concentration of PMNs in the
blood were performed on 29 of the 37 CF+P patients (Fig. 4).
The concentration of G-CSF in the sera was inversely
correlated to FEV1 ( p <0.009, Rho=0.458) and FVC
( p <0.02, Rho=0.400). Lung function and the concen-
tration of G-CSF in sera was measured in 34 of the 37 CF + P
patients.
3.5. Antibiotic treatment and lung function (Fig. 5)
After elective antibiotic treatment the lung function was
measured as FEV1 and FVC. Both FEV1 and FVC wereFVC
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Fig. 5. The lung function before and after elective antibiotic treatment of
15 CF patients with chronic P. aeruginosa lung infection. Wilcoxon signed
pair-differences rank test was used for statistical analysis.
100
1000
m
ea
n
 fl
uo
re
sc
en
ce
CD16
pre            post 
p<0.01
10
100
1000
10000
CD62L
pre            post
p<0.03
Fig. 7. The expression of CD16 and CD62L on in the peripheral blood
before and after elective antibiotic treatment of 15 CF patients with chronic
P. aeruginosa lung infection. Wilcoxon signed pair-differences rank test
was used for statistical analysis.
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elective anti-biotic treatment were included. One patient was
unable to perform the lung function test before treatment.
3.6. Antibiotic treatment and G-CSF and PMNs in the blood
(Fig. 6)
Antibiotic treatment may reduce the inflammatory
parameters, including the number of PMNs, in the lungs
[15,16] (Fig. 6). After the course of treatment, a reduction of
the concentration of G-CSF in the sera ( p <0.05) and the
concentration of PMNs in the blood ( p<0.05) was seen.
3.7. Antibiotic treatment and CD16 and CD62L expression
on PMNs (Fig. 7)
As a measure of PMN activation the expression of CD16
( p <0.01) and CD62L was included (Fig. 7). An increased
expression of CD16 ( p <0.01) and CD62L ( p <0.03) waspre post0
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Fig. 6. The concentration of G-CSF in the sera and PMNs in the peripheral
blood before and after elective antibiotic treatment of 15 CF patients with
chronic P. aeruginosa lung infection. Wilcoxon signed pair-differences
rank test was used for statistical analysis.observed on the PMNs in the peripheral blood from the 15
patients after elective antibiotic treatment.4. Discussion
G-CSF production is primarily confined to monocytes/
macrophages, fibroblasts, and endothelial cells [20] and is
enhanced in response to bacterial products and inflamma-
tory mediators [21–23], such as tumor necrois factor
(TNF)-a [24]. During intrapulmonary infections G-CSF
production is increased exclusively in the lungs from where
G-CSF is released to the circulation resulting in a non-
compartmentalized distribution [25]. In addition, a pulmo-
nary inflammatory response is accompanied by an increased
concentration of G-CSF in the blood in humans after
bronchial endotoxin instillation [26], indicating a non-
compartmentalized distribution of G-CSF during local
inflammation in contrast to, e.g. TNF-a and IL-8. In this
study, the G-CSF concentration in the sera was correlated to
the concentration of the inflammatory marker, TNF-a, in the
sputum in the CF+P patients. Thus, the increased G-CSF
concentration in the sera of the CF+P patients may probably
be derived from the inflammatory response of the infected
lung tissue.
G-CSF is a major mobilizer of PMNs from the bone
marrow [27–29]. Accordingly, the increased concentration
of G-CSF in the sera of the CF+P patients provides an
explanation for the increased concentration of PMNs in the
blood. In addition, after antibiotic treatment a reduction of
both the concentration of PMNs and G-CSF in the blood
was seen.
Apart from modulating the production and mobilization
of PMNs in the bone marrow, G-CSF may affect the surface
expression of adhesion molecules and Fc-g receptors on the
PMNs [30,31]. In this respect, the increased expression of
CD16 and CD62L on the circulating PMNs from CF+P
P.Ø. Jensen et al. / Journal of Cystic Fibrosis 5 (2006) 145–151150patients after antibiotic treatment may be caused by the
reduced concentration of G-CSF in the sera. The direct
influence of the i.v. antibiotic treatment on the PMNs was
also considered. Though a direct effect of the antibiotics
cannot be ruled out in this study, the below proposed direct
effects of antibiotics was not seen. The ability of gentamy-
cin to reduce PMN chemokinesis [32] was not reflected in
the results. On the contrary, despite that a reduced PMN
chemokinesis predicts a longer transit time in circulation
leading to an increased concentration of PMNs, a lower
concentration of PMNs was observed after antibiotic
treatment. The capability of aminoglycosides to affect the
phagocytic activity [33] and respiratory burst on the PMNs
[34,35] may change the fractions of PMNs with phagocytic
activity and respiratory burst of the PMNs. However,
changed fractions of PMNs with phagocytic activity and
respiratory burst were not found (data not shown).
The concentration of PMNs in the blood did not correlate
to the concentration of G-CSF in the sera nor to the
concentration of TNF-a in the sputum in the CF+P patients.
This may be explained by individual responsiveness to
G-CSF and neutrophil transit-time in the blood. Moreover,
G-CSF may affect the lung inflammation by inducing a Th-
2 dominated immune response [36].
The inverse relation of G-CSF in the sera to the lung
function may reflect the dependency of pulmonary G-CSF
production and release in response to inflammatory medi-
ators and bacterial products [21–24] suggesting that G-CSF
has an impact on the neutrophil dominated lung inflamma-
tion by regulating the number of PMNs available for
migration in parallel with casein induced inflammation of
the peritoneal cavity [27]. The involvement of PMN
migration in the lung inflammation is indicated by the
inverse relation of the concentration of PMNs in the blood
to the lung function. Thus, being released from the
chronically infected lungs, G-CSF may sustain the persistent
PMN dominated response by stimulating the production and
mobilization of PMNs in the bone marrow. Furthermore, the
postponning of PMN apoptosis by G-CSF [23], may also
increase the number of PMNs in the lungs.
Increased pulmonary concentration of IL-8 is a charac-
teristic of CF patients with chronic P.aeruginosa lung
infection [37,38]. The reduced neutrophil influx by neutral-
ization of IL-8 by anti-IL-8 antibodies has shown that IL-8 is
a part of the chemotactic gradient that attracts the PMNs to
the site of inflammation [39,40]. Surprisingly, the results in
this study show a higher IL-8 concentration in the blood of
the non-infected CF patients. However, lung bacteriology
did not relate to the serum concentration of IL-8 in another
study of CF patients [41,42] and IL-8 measurement in the
sera may be difficult to interpret due to the presence of
autoantibodies [43].
The effect of IL-8 in the circulation on the number of
PMNs released from the bone marrow is a paradox. IL-
8 increases the mobilization of PMNs [44], but inhibits the
neutropoiesis in the marrow [45,46]. This suggests that IL-8 in the blood may not be able to sustain a persistent
migration of PMNs to the lungs. Accordingly, the results of
this study show no correlation of the IL-8 concentration in
the sera to the concentration of PMNs in the blood nor to
the lung function. Therefore the proinflammatory effect of
IL-8 in the CF+P patients is likely to be confined to the
lungs.
In conclusion, the actual extent of inflammation may be
reflected in the G-CSF concentration in the sera in stable,
chronically infected CF patients without exacerbations. It is
widely recognized that C-reactive protein (CRP) may serve
as a useful systemic marker of lung inflammation during
exacerbations in chronically infected CF patients. However,
CRP has not been useful for assessing the inflammation in
stable, chronically infected CF patients without exacerba-
tions receiving elective 2 week courses of antibiotics every
third month as only a few of these patients had increased
CRP and it was only a modest increase [47,48]. The present
study suggests that the concentration of G-CSF in circula-
tion may be an alternative to CRP to be considered for
estimating the ongoing lung inflammation in stable chron-
ically infected CF patients without exacerbations.Acknowledgements
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